Clinical Trials Logo

Lung Tumor clinical trials

View clinical trials related to Lung Tumor.

Filter by:

NCT ID: NCT06397807 Not yet recruiting - Lung Cancer Clinical Trials

Postoperative Pain Management on Patients Undergoing Lung Tumor Resection

Start date: May 31, 2024
Phase:
Study type: Observational

Multimodal analgesia (MMA) is an essential part of Enhanced Recovery After Surgery (ERAS) protocol. The principle of MMA is to manage pain with analgesics of multiple classes acting on distinct target sites through different strategies. MMA can reduce the adverse reaction caused by opioids and improve the quality of recovery from surgery. Inadequate postoperative pain management will increase the risk of complications, including pneumonia, deep vein thrombosis, infection, delayed surgical healing, and chronic postoperative pain.

NCT ID: NCT06322329 Recruiting - Lung Tumor Clinical Trials

RealMove (Lung): Assessing Tumour Motion With Dynamic MRI

RealMove(lung)
Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The study aims to develop an improved method to tailor the geometric safety margin when treating with stereotactic body radiotherapy (SBRT), to avoid tumour cells being missed during irradiation and to limit the exposure of normal tissues as much as possible. Dynamic magnetic resonance imaging (MRI) is assumed to represent the tumour motion during the respiratory cycle more realistically, compared to 4-dimensional computed tomography (4D CT), thanks to its high temporal resolution and the possibility to image the motion over a longer period of time. Patients receiving SBRT for a pulmonary target located below the level of the carina are included in the study, and the hypothesis will be tested through a comparison of the tumour amplitude measured with each modality. Furthermore, the predictive value of the image series acquired at treatment planning, for the motion patterns observed at each treatment fraction, will be evaluated through repeated 4D CBCT acquisitions.

NCT ID: NCT05555342 Active, not recruiting - Metastatic Cancer Clinical Trials

A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm

Start date: January 3, 2023
Phase: Early Phase 1
Study type: Interventional

This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.

NCT ID: NCT05279521 Not yet recruiting - Lung Cancer Clinical Trials

The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.

Start date: March 20, 2022
Phase: N/A
Study type: Interventional

This study concluded that lung rehabilitation exercise programs can improve the psychological distress, self-efficacy, quality of life, six-minute walk distance, muscle strength, and reduce the number of hospitalizations for patients with advanced lung cancer.

NCT ID: NCT05169437 Active, not recruiting - Pancreatic Cancer Clinical Trials

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

PAVO
Start date: March 15, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.

NCT ID: NCT04974632 Recruiting - Lung Tumor Clinical Trials

Mobile 3D C-arm CT for Lung Tumor Localization Efficacy Analysis: a Prospective Clinical Trial

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

It is well known that video-assisted thoracoscopic surgery (VATS) is preferred to open surgery for lung resection because of the smaller incisions and optimized postoperative recovery, including a shorter length of hospitalization and much decreased local tenderness. Studies have shown less operative and post-operative morbidity with decreased operative times. However, for small nodules (i.e. lesions <1 cm or those at a distance more than 1.5cm from the lung periphery), adequate identiļ¬cation of the target nodule has been being difficult by VATS with necessity of more significant resection or thoracotomy conversion to ensure complete tumor resection. In order to improve nodule localization, a variety of preoperative localization methods such as CT-guide hook wire or methyl blue dye localization have been proposed. It has been proved to be much easier to mark lung nodules and help guide resection during VATS. However, there are certain concerns. First, it is difficult to minimize the time between the localization procedure and the subsequent surgery in reality. Second, there is concern for patient safety, in particular pneumothorax or hemothorax, during transferred to and from the ward to the radiology suit and in the frequent delays and waiting in reception areas prior to transfer to operating theaters. Finally, interdepartmental transfers and delays can also increase the risk of hook wire dislodgement. Theoretically, the aforementioned disadvantage could be solved by performing the localization procedure and the lung surgery in the same operating room environment. We performed single-step localization and removal of small pulmonary nodules in the hybrid OR equipped with floor-mounted C-arm cone-beam computed tomography (CBCT) in the previous study. However, it costed a lot of money and every localization could only be performed in the hybrid OR. Mobile 3D C-arm CT is another form of CBCT. It depicts soft tissues with high contrast but also offer a more affordable solution with relative low cost. In this case series, we will investigate the use of a mobile 3D C-arm CT for single-step localization and removal of small pulmonary nodules.

NCT ID: NCT04917224 Withdrawn - Lung Cancer Clinical Trials

Study of LUNG Stereotactic Adaptive Ablative Radiotherapy

LUNG STAAR
Start date: May 2, 2022
Phase: N/A
Study type: Interventional

The proposed study expands on the principles of SBRT (Stereotactic Body Radiation Therapy) and SABR (Stereotactic Ablative Radiotherapy) for centrally located NSCLC (Non-Small Cell Lung Cancer) to further optimize outcomes in this patient population with utilization of the adaptive workflow to maintain tumor control rates but decrease the incidence and grade of treatment-related toxicities.

NCT ID: NCT04075305 Recruiting - Breast Cancer Clinical Trials

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

MOMENTUM
Start date: February 1, 2019
Phase:
Study type: Observational [Patient Registry]

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

NCT ID: NCT04056273 Recruiting - Diagnoses Disease Clinical Trials

Assess the Use of rEBUS With a Guide Sheath to Increase Transbronchial Lung Biopsy Yield Rate

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Whether using a guide sheath can increase the diagnostic yield rate after the lesion is located by radial endobronchial ultrasound

NCT ID: NCT03972228 Completed - Lung Cancer Clinical Trials

Microdevice for Evaluating Drug Response in Site in Lung Lesions

Start date: October 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a pilot study for placement of a tiny microdevice into lung tumors to more precisely predict tumor-specific drug sensitivity, and to help inform systemic therapeutic decisions. The microdevice will provide a novel technique for interrogating human lung tumor tissue in situ, and will uniquely facilitate assessment of response to multiple drugs simultaneously. This will not only increase the specificity of a particular participant's chosen systemic therapy, it will also augment the speed and efficiency with which investigators are able to make clinical decisions regarding choice of therapy.